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Abstract
Purpose The aim of non-interventional studies (NIS) with
medicinal products is to investigate the use of authorized
medicinal products in daily routine. In the past, this type of
study has been subject to frequent criticism, and many
recommendations have been published. The aim of our
study was to assess the quality of NIS study protocols.
Methods Nearly all NIS study protocols submitted to the
German Federal Institute for Drugs and Medical Devices
(BfArM) within a period of one year could be analyzed. The
protocols were evaluated in terms of objectives, methods
and included patients, as well as with regard to their com-
pliance with quality recommendations for NIS by federal
authorities and pharmaceutical industry associations.
Results The 136 NIS available for study were scheduled to
enroll approximately 330,000 patients (2,500 patients per
study) and 43,000 healthcare professionals. Of these NIS,
58 % were performed with medicinal products that had been
authorized within the past 5 years; however, 68 % of the
investigated active pharmaceutical ingredients were older
than 5 years, and 19 % were even older than 19 years.
Only 56 % of the protocols provided information on publi-
cation policy, and 65 % required the involvement of ethic
committees. The adherence to current quality recommenda-
tions was average, but the compliance of NIS performed by
member companies of the Association of Research-Based
Pharmaceutical Companies was significantly higher than
that of other sponsors.
Conclusions Current quality recommendations are still not
fully implemented in most NIS protocols. Therefore, the
scientific value of many NIS is still questionable, and the
criticism that NIS are mainly conducted for marketing rea-
sons could not be refuted by the data analyzed here.
Keywords Cross-sectional analysis . Non-interventional
study . Observational study . Federal Institute for Drugs and
Medical Devices . Post-authorization safety studies
Introduction
In the European Union (EU), a marketing authorization is the
legal prerequisite for placing a new medicinal product on the
market. In order to be granted this authorization, the manu-
facturer has to prove the efficacy and safety of his product by
using controlled, randomized Phase II and III clinical trials
[1]. The high internal validity of the results of properly
conducted randomized clinical trials (RCTs) is well accepted;
consequently, RCTs have become the gold standard for prov-
ing the efficacy of medicinal products [1–3]. However, there
are certain questions which cannot be answered by random-
ized trials—or only with enormous and disproportional effort
[2, 3]. Due to the fact that clinical trials are performed under
strictly controlled conditions and protocols, they can provide
only limited information about the usage of a medicinal prod-
uct in daily routine [3, 4]. This includes, for example, incom-
plete information about medical prescription practice, dosage
adaptations by the physician or patients’ compliance [5]. As a
result of the strict inclusion and exclusion criteria, the patients
of a clinical trial are usually not a fully representative sample
of the actual population, and certain populations are under-
represented [2, 3, 5]. Therefore, the information about the
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influence of concomitant diseases and medications typically
gained in such trials can only be incomprehensive [3, 6]. Since
clinical trials are subject to time constraints and contain small
study populations, only limited data can be collected on long-
term safety and effectiveness, as well as on rare adverse drug
reactions (ADR) [1, 2, 4, 5].
In the Clinical Trials Directive 2001/20/EC, the EU has
legally defined the non-interventional study (NIS) as opposed
to the clinical trial. Article 2c defines the term “non-interven-
tional” as follows: “a study where the medicinal product(s) is
(are) prescribed in the usual manner in accordance with the
terms of the marketing authorization. The assignment of the
patient to a particular therapeutic strategy is not decided in
advance by a trial protocol but falls within current practice
and the prescription of the medicine is clearly separated from
the decision to include the patient in the study. No additional
diagnostic or monitoring procedures shall be applied to the
patients and epidemiological methods shall be used for the
analysis of collected data” [7]. The German legislative author-
ity transferred the NIS definition into national law in 2004 with
the 12th AMG (German Medicinal Products Act) amendment
[8]. It has become obligatory in subsequent amendments to the
AMG to notify the German federal competent authorities prior
to commencement of an NIS [9]. The legal specifications for
NIS predominantly allow observational studies to be conducted
with the aim of gaining scientific knowledge on such subjects
as long-term safety rather than efficacy/effectiveness, rare
ADR, the usage of a medicinal product in daily routine or the
influence of concomitant diseases and medications, among
others. While clinical trials focus on efficacy, NIS tend to focus
more on effectiveness, which is efficacy under real-life condi-
tions. Interventions differing from clinical routine or randomi-
zation of patients’ treatment are not consistent with the legal
requirements.
NIS have been criticized frequently over the past years.
They have been accused of poor scientific quality, and it is
alleged that the pharmaceutical companies as sponsors of these
studies are more interested in marketing their medicinal prod-
ucts than in gaining additional scientific knowledge [3, 5,
10–15]. As a consequence of this criticism, there have been
different attempts in Germany to raise the quality of the NIS.
Starting in 1998, the Federal Institute for Drugs and Medical
Devices (BfArM), the German higher federal authority for
authorization of most of the medicinal products for human
use in Germany, published recommendations for planning
and conducting NIS [16]. These recommendations were re-
vised in the course of the AMG amendments in cooperation
with the Paul-Ehrlich Institut (PEI), published for public con-
sultation in 2007 and finalized after minor modifications in
2010 [17–19]. This compilation includes information about the
definition and possible objectives of NIS, about the observa-
tional plan, the analysis plan, quality management, patient’s
consent and education, conflicts of interests, duty to notify and
recommendation to report, publishing, archiving and finally
reimbursement of the participating healthcare professionals
(HCPs). The “Association of Research-Based Pharmaceutical
Companies” (VFA) and the organization for “Voluntary Self-
regulation for the Pharmaceutical Industry” (FSA) have also
both published recommendations and procedures for NIS
which are binding for their member companies. The VFA
recommendations amplify the 2007 recommendations of
BfArM and PEI andwere also published in 2007. They include
additional recommendations for the internal responsibility for
the study, patient’s informed consent, involvement of indepen-
dent ethics committees, publication policies for study results,
as well as public study registers and the need to establish
standard operating procedures for planning and conducting
NIS [18, 20]. The FSA code requires following the BfArM
and PEI recommendations and requests additional procedures
for conducting NIS. These procedures include the same rec-
ommendations as those of the VFA but additionally require
obligatory scientific objectives. Furthermore, they contain ad-
vice on quality management, content and function of the
observational plan, analysis of the results and reim-
bursement of the participating HCP [21]. In addition
to these, there have been many other publications with
recommendations for enhancing the quality of NIS, in-
cluding guidelines and recommendations for assurance
of good epidemiological practice [4, 5, 13, 22–26].
In view of the continuing criticism of NIS, it is unclear
whether the numerous recommendations are being followed
and whether an improvement in NIS design can be ob-
served. Therefore, the aim of the study reported here was
to investigate the quality of NIS by analyzing their obser-
vational plans in a nearly complete cross-sectional analysis.
Until 2009 the competent authorities (BfArM or PEI) in
Germany had only to receive notification of an NIS—and
then only if the NIS were performed on behalf of pharma-
ceutical entrepreneurs. The legal basis for such notifications
did not include the obligation to also submit the observa-
tional plan. This was changed in the 15th amendment of the
German Medicinal Products Act in 2009. Since then, phar-
maceutical entrepreneurs are also obliged to submit the
observational plan together with the notification of a NIS
[27]. This change in legislation opened the door to analyses
of observational plans of NIS sponsored by pharmaceutical
companies by non-participating third parties and/or without
major selection bias.
Methods
Study design This study evaluated the quality of NIS by
analyzing the content and quality of their respective obser-
vational plans. The goal was to analyze the observational
plans of all NIS submitted to the BfArM within 1 year after
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the new legal requirements for NIS came into force in
Germany. All available observational plans were reviewed
according to a standardized review procedure, and the sci-
entific quality evaluation was performed using a predefined
scoring system. The authors who performed the investiga-
tion are organizationally in a department where they are not
involved in—and thus independent of—the BfArM NIS
assessment. Even though this study is not an observational
study in the classical sense, the reporting of the results is
based on the STROBE statement [28].
Setting All NIS of which the BfArM was notified during the
period from September 1, 2009 to August 31, 2010 and for
which the BfArM is the competent authority were included
in the investigation. NIS that commenced prior to
September 1, 2009, report updates and amendments and
extensions of ongoing NIS that were started prior to
September 1, 2009 as well as NIS for which the PEI is the
competent authority were excluded.
Data set selection/study size A total of 387 submissions
were reviewed and assessed for inclusion and exclusion
criteria; 136 NIS of these remained evaluable and were
subsequently included in the analysis (Fig. 1).
Variables A standardized data set was assessed for each
NIS. Aside from administrative data, the variables in
Table 1 were recorded and entered into the study database.
Variables were either encoded dichotomously (“yes”, “no”),
as respective numbers or as free text. Data not available in
the NIS protocol were recorded as missing data (“not avail-
able”).
Data sources The sponsoring companies of each NIS were
categorized in accordance with their membership in the VFA
[29]. It was also checked whether the NIS had actually been
registered in the NIS register of the VFA as planned [30]. The
German federal drug information system (AMIS) was used to
gain information on the date and status of marketing authori-
zation of the medicinal product, the respective active pharma-
ceutical ingredients (API) and the originator of the medicinal
product(s) with the respective API [31]. For further classifi-
cation of the API, the Anatomical Therapeutic Chemical
(ATC) classification system was used [32]. The summary of
product characteristics (SmPC) of the specific medicinal
product was used to compare the dosage information
and indications given in the observational plan with
those given in the SmPC.
Measurements An evaluation was performed if the diagnostic
and therapeutic procedures of the NIS and the documentation
requested from the HCPs were consistent with usual medical
practice and if no additional diagnostic or monitoring
procedures were applied (in accordance with the requirements
of European Directive 2001/20/EC and the applicable national
legal requirements) [7]. The assessment of compliance of the
diagnostic and therapeutic procedures with clinical practice
was performed by both authors jointly in a semi-blinded de-
sign: the senior expert who performed the major rating was
blinded with respect to the company and the specific product,
while the second author presented the setting. The assessment
was based on the SmPC, German and European expert guide-
lines and recommendations of German and European scientific
societies. A four-point scale was used to rate the adherence to
these guidelines: completely consistent with current medical
practice (procedures performed completely within the guide-
lines); partially consistent with current medical practice (addi-
tional procedures were only performed if decided by the HCP
and could be counted as current medical practice); partially not
consistent with current medical practice (additional procedures
were only performed if decided by the HCP but procedures
could not be counted as current medical practice); not
All documents
N = 387
Not related to NIS = 3
Documents related to NIS 
N = 384
Excluded (Total = 243)
- No new notifications = 206
- Repeated notification of same study = 21
- NIS commenced prior to 01/09/09 = 8




- No tavailable for analysis  = 5
Data available for analysis 
N = 136
Fig. 1 Data set selection/study size. All documents associated with the
topic non-interventional studies (NIS) and collected in the chosen time
period were selected from the archive of the Federal Institute for Drugs
and Medical Devices (BfArM). The resulting 387 documents were
screened. Three documents were excluded since they were not related
to an NIS. Of the remaining 384 documents, 243 NIS documentations
were excluded for the following reasons: the NIS were not new
notifications but additional information on running studies (n=206);
repeated notifications of already notified NIS (n=21); NIS that had
been commenced prior to September 1, 2009 (n=8); the NIS was not
within the competence of the BfArM (n=8). Of the 141 studies that
were not excluded, five NIS were not available for review due to in-
house processes
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consistent with current medical practice at all (additional pro-
cedures required by the protocol). The quality of the observa-
tional plans was rated using a specially developed scoring
system. The observational plans could reach a score of 25 by
fulfilling requirements (score items) of the recommendations
for developing and conducting an NIS published by the com-
petent authorities (BfArM and PEI) [17]. A “bonus” score of
up to 6 could be reached if the extra VFA and FSA recom-
mendations, i.e, over and above those of the BfArM/PEI, were
followed [20, 21]. The score items are depicted in detail along
with the results in Table 2. Each score item was weighted
equally. In cases where no data on a certain score item were
provided in the observational plan, the score item was counted
as not fulfilled. A maximum score of 25 (+ 6) was assigned
when all requirements of the BfArM/PEI and VFA/FSA rec-
ommendations were addressed and fulfilled.
Statistical methods The statistical analysis was performed
using the IBM© SPSS© Statistic software package ver. 20
for Microsoft Windows operating systems (SPSS, Chicago,
IL). Categorical variables were evaluated using absolute num-
bers, frequencies and percentages, while discrete variables
were evaluated using numbers, frequencies, mean, minimum,
maximum, percentile and median. On the basis of free-text
variables, a division into subgroups was performed. A non-
parametric Mann–Whitney U test was carried out to compare
the recommendation compliance of member companies of the
VFAwith that of non-member companies.
Results
Sponsors, study location and study duration
The 136 reviewed NIS were initiated by 73 different
sponsors, of which. 96 % were pharmaceutical companies
that conducted nearly 98 % of the NIS under review.
Table 1 Variables recorded from observational plans during standardized data set
Recorded variables
General data on NIS Data on NIS setting
Internal document number Number of visits
Study title Entire duration of the NIS
Initiator Observation period for each patient
Contract research organization Number of healthcare professionals involved
Study location (country) Specialty of healthcare professionals involved
Provided rationale for choosing a non-interventional design Place of the observation (private practice, hospital, pharmacy)
Number of patients to be observed
Information on medicinal product Justifications for sample size/sample size calculation
Brand name(s) Determined number and average number of patients observed by each
healthcare professional
Active pharmaceutical ingredient(s) Recruiting process for patients and healthcare professional
Medical indication Inclusion process for patients
Dosage information Analyzed moment of treatment in course of therapy (e.g. start of or
change in therapy)
Reporting of adverse drug reactions
NIS objectives Study design
Rationale Interim analysis
Objectives Publication policy
Measurements Reporting results to the participating healthcare professional
Discussion of potential confounders Quality assurance/Data management
Measures for controlling confounders Statistical analysis
Archiving of the study data
Data on survey instrument Data transfer (pseudonymized/anonymized)
Case report forms used Patients’ informed consent
Content of the case report forms Registration in the VFA register for NIS [30] or another public register
Special questionnaires Involvement of ethics committees
Opinion of ethics committee
NIS, Non-interventional study; VFA , Association of Research-Based Pharmaceutical Companies
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Three studies were submitted by non-pharmaceutical
companies, two of them by hospitals and one by a
contract research organization (CRO) which did not pro-
vide information on the sponsoring client. Approximately
one-fourth of the sponsors were VFA member companies
and initiated approximately 35 % of the NIS. Geographic
information on centers was provided in approximately
90 % of the observational plans: 68 % of the NIS were
supposed to be conducted as multicenter NIS with no
regional restriction in Germany, 2 % were located in one
German Federal Land only and 4 % of the NIS were
conducted in a mono-centric setting. Approximately
20 % of the NIS were reported as multinational studies.
All observational plans, with two exceptions, contained
information on the planned total study duration. One-
fourth of the studies had been designed to last more than
24 months, around 35 % to last between 13 and
24 months and 38 % of the protocols provided for a
study duration of 12 months or less. The distribution of
the individual observational period for each patient is
presented in Table 3 (13 % of the protocols did not
provide data on this topic). For 48, 22, 6 and 6 % of
the NIS, up to three, four to six, seven to nine and more
than nine visits per patient were scheduled, respectively,
while 18 % of the protocols did not provide any infor-
mation on the number of visits per patient.
Table 2 Distribution of NIS
which fulfilled the score items of
the recommendations of the
competent authorities or phar-
maceutical industry societies
BfArM, Federal Institute for
Drugs and Medical Devices;
PEI, Paul-Ehrlich Institute; FSA,
Voluntary Self-regulation for the
Pharmaceutical Industry; ADR,
adverse drug reactions
A NIS could be scored only once
for each score item, and each
score item was equal in value
aPrecise objective: NIS could be
scored if the objective concerned
one of the following questions:
(1) safety/ADR; (2) observation
of use in everyday life (e.g. num-
ber of visits, dosage informa-
tion); (3) influence of individual
patients’ factors on therapy (e.g.
age, concomitant therapy, con-
comitant disease); (4) quality of
life; (5) compliance
bSuitable outcome measurement:
NIS could be scored if the objec-
tive was measured with one of
the following measurements: (1)
number of ADRs; (2) laboratory
results; (3) examination results:
(4) dosages; (4) results of special
questionnaires
Scoring system n Percentage (%) of
NIS fulfilling score
items
Score items of the recommendations of the competent authorities (BfArM and PEI)
Definition of a precise objectivea 122 89.7
Definition of a suitable outcome measurementb 99 72.8
Provided rationale for choosing a non-interventional design 48 35.3
Discussion of influencing variables 9 6.6
Discussion of confounders 9 6.6
Measures for controlling of confounders 5 3.7
Existence of sample size calculation for study population 15 11.0
Prospective cohort study 133 97.8
Investigation of a reference group 6 4.4
Requiring a patient’s informed consent 102 75.0
Requiring the involvement of an ethics committee 88 64.7
Reporting system for ADR 130 95.6
Information on archiving study data 76 55.9
Data on publication policy in general 75 55.1
Planned publication within certain time period 16 11.8
Definition of inclusion criteria 110 80.9
Definition of exclusion criteria 92 67.6
Description of the patient recruitment process 26 19.1
Data on the overall study duration 134 98.5
Data on the survey instrument(s) used in the study 133 97.8
Definition of a person in charge of the conduct of the NIS in the respective
pharmaceutical company
24 17.6
Data on quality assurance/data management 124 91.2
Data on statistical analysis 126 92.6
Partially or completely consistent with current medical practice 114 83.2
Completely consistent with current medical practice 63 46.3
Score items of the recommendations of the societies of pharmaceutical industry (VFA and FSA)
Definition of standard operating procedures 11 8.1
Planned training of the participating employees 13 9.6
Registration of the study in a public register 35 25.7
Definition of a rationale 58 42.6
Presence of a written observational plan 136 100
Planned reporting of results to the participating healthcare professionals 10 7.4
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Publication policy
Of the investigated protocols, 56 % provided information on
the publication policy. A statement that a publication of the
results was at least planned was contained in 43 % of the
NIS protocols; an additional 11 % stated that a publication
was planned within a certain time period, and 7 % contained
statements that the results would be reported to the participating
HCP. One-fourth (26 %) of the protocols provided for study
registration in public study registries and 50 % in the VFA
register for NIS [30]. Review of this register revealed that one
of the NIS for which a registration in that register had been
announced was recorded with information on the start of the
study which was not consistent with the observational plan.
Data protection, informed consent and ethics committees
Patient informed consent was required in 75 % of the NIS,
while 7 % explicitly stated that no patient informed consent
was required; the remaining 18 % of the NIS did not provide
information on this topic. A pseudonymized transfer of
patient-related data from the investigator to the sponsor/CRO
was scheduled in 73% of the NIS protocols, while 17% of the
protocols reported a complete data anonymization before data
transfer; 10 % of the protocols did not provide information on
data protection and data transfer. Interestingly, only 81 % of
the NIS reporting a pseudonymized data transfer (73 %) also
provided for an informed consent. Of the 44 % of the NIS
protocols that specified monitoring of the study in the obser-
vational plan, less than half had stipulated an informed consent
of the patients on this subject. Approximately two-thirds
(68 %) of the NIS protocols contained information on the
involvement of an ethics committee, with 65 % requiring the
opinion of at least one ethics committee while 2 % explicitly
declined the involvement of any ethics committee. Two pro-
tocols of internationally performed NIS stated that the opinion
of an ethics committee would be requested if demanded by
national legislation but did not provide information on wheth-
er an opinion was requested in Germany. For 10 % of the NIS
reviewed, the favorable opinion of an ethics committee was
attached to the study protocols.
Study design
In terms of study design, 85 % were prospective, 2 % were
retrospective and 13 % had a prospective design with retro-
spective parts. The settings were multicentric in 93 % of the
NIS and monocentric in 4 %; five protocols did not provide
Table 3 Distributional on NIS reviewed
Distributional data on NIS
Distribution of number of patients, number of healthcare professionals, number of patients per investigator and observational period (days) for each
patienta
Mean Median Maximum Range 25th–75th Percentile
Number of patients 2,445.6 600 30,000 29,980 300–1,500
Number of healthcare professionals 364.5 120 3,000 3,000 30–340
Number of patients per healthcare professional 15.4 5 500 499 3–8
Observational period for each patient (in days) 292.4 180 3,650 3,649 59–365
Distribution of the 10 % of the NIS with the highest numbers of recruited patients
Number of patients
X-ray contrast agent 30,000
X-ray contrast agent 25,000
X-Ray contrast agent 20,000
Antidepressant 20,000
Eye drop (ocular hypertension and open-angle glaucoma) 15,000
Antihypertensive agent 15,000
Antihypertensive agent 15,000
Eye drop (ocular hypertension and open-angle glaucoma) 12,800
X-ray contrast agent 12,000
Antibody (oncology therapy) 12,000
Thrombocyte aggregation inhibitor 10,000
Oral antidiabetic drug 10,000
X-ray contrast agent 10,000
a If defined precisely in the observational plan in advance
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information on this topic. In terms of number of study arms,
95% of the NIS were performed as a single-arm study, and the
remainder were performed as two-arm or even multiple-arm
studies. Thirteen percent of the investigated NIS described an
additional subgroup analysis. The rationale for choosing a NIS
design was not discussed in 65 % of the studies.
Recruitment and sample size
Provisions regarding the mode of patient recruitment were
included in 19 % of the NIS protocols, and 41 % provided
information on the method of recruiting the participating
HCP. Information on the location where the investigation
was scheduled to take place was provided in 66 % of the
NIS. Most of the NIS were performed in private practices
exclusively (38 %) or in private practices and hospitals
(23 %). Only 4 % of the NIS were exclusively performed
in hospitals, and two NIS were planned to be performed in
pharmacies only. Information on the specialization of the
participating HCPs was provided in 70 % of the protocols,
with the majority focusing on general practitioners and
internists [for additional information, see Electronic
Supplementary Material (ESM) 1]. All protocols except
for one defined the number of participating HCPs, and
88 % provided a sample size for the patient population, with
43 % of the protocols defining the number of patients per
HCP. The distribution is presented in Table 3. The 136
reviewed protocols included over 330,000 patients exam-
ined by approximately 43,000 HCPs. A justification of the
sample size was provided by 58 % of protocols, but a
sample size calculation by effect estimation was performed
in only 11 % of the NIS; 35 % justified the sample size by
the width of a predefined confidence interval and 12 %
justified the sample size by simply declaring their sample
size as appropriate for answering the study objectives.
Medical indications
With regard to the inclusion process for patients, 95 % of the
NIS provided data on the stage of treatment in which the
patients should be recruited for the study. In most of the
NIS, the patients were supposed to be recruited at the
beginning of the treatment with the investigated medicinal
product (68 %), in 35 % of the NIS, the patients were to be
recruited during therapy, in 14 % after a change in therapy
and in one case the intention was to recruit the patients after
therapy (multiple answers were possible). Data on inclusion
and exclusion criteria for patients were provided by 81 and
68 % % of the NIS, respectively. The most frequently
specified inclusion criteria were presence of a certain medical
condition (66 %) followed by patient characteristics (e.g. gen-
der, body weight, height; 45% and a certain medical history of
the patient (27 %). The presence of contraindications (39 %)
followed by the presence of a certain medical condition (25%)
and concomitant therapies (24 %) were the most commonly
specified exclusion criteria. Pregnancy or nursing were speci-
fied as exclusion criteria in 17 % of NIS, and patients with
known hypersensitivity to one or more ingredients were
excluded in 16 % of the NIS. A medical condition in the
observational plan was specified in 93 % of NIS protocols
which complied with the marketing authorization conditions
specified by the SmPC in all instances. The remaining pro-
tocols did not provide a medical condition as inclusion criteri-
on. The investigated medical conditions are presented in Fig. 2.
Fig. 2 Medical conditions
investigated by the NIS under
review. NIS investigating
malignant tumors were
summarized in the category
“Oncology” only and excluded
from other categories (indicated
with an asterisk)
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Objectives
All NIS protocols provided information on the primary objec-
tive(s), whereas 62 % of the protocols discussed the scientific
rationale for the study itself. Nearly one-quarter of the inves-
tigated NIS specified a new, currently not investigated objec-
tive as the reason for conducting the NIS. Around 10 % of the
NIS were conducted either to investigate a larger collective
and/or use in everyday life, to confirm results of prior studies
or upon recommendation of competent authorities, 7 % were
performed to observe new dosages, 4 % were long-term
observations and 7 % of the rationales were imprecise and
not clear. The objectives defined are presented in Table 4.
Objectives were measured by number of the ADR (52 %),
score items in the case report forms (CRF) measuring the
success of therapy (48 %), results of laboratory tests or results
of examinations (33 %), results of special questionnaires
(28 %) or dosages (12 %) (multiple answers were possible).
Information on the primary measurements was not specified
in 12 % of all protocols.
CRF, questionnaires and data management
In 71 % of the NIS protocols, the CRF were filled in only by
the HCP, in 27 % by the HCP and the patient and in one NIS
only by the patient. Additional information on the content of
the CRF is given in ESM 2 and information on the content of
special questionnaires is given in ESM 3. Information on data
management and quality assurance was provided by 91 % of
the NIS. Some kind of monitoring was planned for nearly one-
half of the NIS (44 %). Furthermore, 56 % of the protocols
provided information on the archiving of the study data.
Detailed information on data management, quality assurance
and classification systems is given in ESM 4. About 93 % of
the NIS specified data on statistical analysis procedures. Such
data were often not very precise and contained only informa-
tion on an analysis of distribution (68 %) or frequencies
(63 %), or differentiated whether a descriptive (57 %) or an
explorative analysis (22 %) was planned.
Medicinal products and API
Most of the NIS (80 %) investigated only one medicinal
product containing one API; 10 % investigated a medicinal
product which was a combination product with more than
one API; 4 % investigated more than one medicinal product
but products with the same API; 5 % investigated different
medicinal products with different API. Approximately two-
thirds of the NIS (66 %) investigated brand-name medicinal
products (originator products), one-third investigated gener-
ic medicinal products and in two studies only the API was
given in the study protocol.
Nearly one-third of the API were classified as antineo-
plastic and immunomodulating agents. Additional informa-
tion on the distribution of the APIs according to ATC code is
given in ESM 5. An analysis of the temporal relation be-
tween the year of first marketing authorization of the inves-
tigated medicinal product and the respective API is provided
in Fig. 3.
Compliance with current medical practice
and recommendations
For 94 % of the NIS an evaluation of the compliance with
current medical practice was performed; such an evaluation
could not be performed for the other 6 % due to lack of
information in the observational plan. Nearly one-half of the
NIS (46 %) could be evaluated as being completely consistent
with current medical practice, while approximately 38, 8 and
2 % were evaluated as being partially consistent, partially non-
consistent and not consistent with current medical practice,
respectively. The scores according to the recommendations of
the German competent authorities (BfArM and PEI) are
presented in Fig. 4 and Table 2, and the additional scores for
the recommendations issued by the VFA and FSA are
presented in Fig. 5 and Table 2 [17, 18, 20, 21]. A comparison
of the results of member companies of the VFA and other
pharmaceutical companies revealed that recommendation com-
pliance by member companies of the VFA was significantly
higher than that of other pharmaceutical companies (p<0.001).
Discussion
In our study we analyzed the quality of 136 NIS protocols
submitted to the BfArM over a 1-year period. The protocols
analyzed could not be classified as high-quality studies







Safety/adverse drug reaction 96 70.6
Observation of application in everyday
life (e.g. number of visits, dosage
information)
56 41.2
Influence of individual patients‘factors
on therapy (e.g. age, concomitant
therapy, concomitant disease)
37 27.2




aMultiple answers were possible
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because the studies only partially fulfilled the recommenda-
tions for conducting NIS by the BfArM and the VFA/FSA.
Furthermore, a remarkably large number of patients was
investigated. The API investigated included on the one hand
expensive drugs and on the other hand also generic products
which have been on the market for more than 5 years.
In contrast to earlier studies, this study investigated a
representative sample since it was possible to investigate
almost all NIS that had been submitted to the BfArM within
the period of 1 year because the new legal regulations
require the submission of observational plans for all newly
notified NIS to the competent authorities in Germany [27].
As expected, most of these studies were conducted as mul-
ticenter studies, but only a small proportion was planned as
multinational NIS. The entire study duration of nearly all
NIS was shorter than 2 years, and the individual observation
period for a single patient was less than or equal to 6 months.
Overall, approximately 330,000 patients were scheduled for
inclusion in all of the 136 NIS, with an average of approx-
imately 2,500 patients per study, which is in the range of
large Phase III clinical trials. All in all, more than 43,000
HCPs participated in the NIS. Although most of the inves-
tigated medicinal products were in the therapeutic fields of
oncology and neurology, most of the NIS were conducted in
the framework of private practices and with general practi-
tioners or internists as investigators.
We evaluated the NIS with regard to their compliance
with the recommendations of the BfArM, VFA and FSA. In
the observed period of time, the scores of the NIS evaluated
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ing API. For an API without determination of a medicinal product, the
year the newest medicinal product with this API was authorized was
chosen. For a therapeutic regimen with different API without determi-
nation of distinct medicinal products, the year the newest API was
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could be found in the middle quintile (Fig. 4). However, the
recommendation compliance of the NIS performed by com-
panies which were members of the VFA was significantly
higher than that of those performed by other pharmaceutical
companies. Interestingly, not even a VFA member company
provided sufficient information in the observational plan to
fulfill the six additional score items of the VFA/FSA rec-
ommendations, but at least two NIS sponsored by VFA
member companies fulfilled five of the six additional score
items. Overall, three-quarters of the NIS provided informa-
tion in the protocol on compliance with only one or two
additional score items (Fig. 5). The most frequently
neglected—or at least not mentioned—VFA/FSA require-
ments were the score items “result reporting to the partici-
pating HCPs” and “definition and use of standard operation
procedures for NIS”; each was missing from approximately
90 % of NIS. Upon closer inspection, the findings on many
score items were disappointing. Only slightly more than
one-third of the NIS provided a rationale for choosing a
non-interventional design, and a little more than one-half of
these provided information on archiving study data or on the
publication policy. Furthermore, only about one-third of the
NIS planned a registration of the study in a public register.
The study designs also exhibited some shortcomings: only
11 % of the NIS protocols described a sample size calcula-
tion, only 5 % analyzed control groups and only 7 % pro-
vided data on confounder analysis.
Overall, the results of our study support the results of
previous studies indicating a more or less unsatisfactory
publication policy in NIS protocols, as already reported by
Windeler and colleagues and de Mey in 2000 [33, 34]. In
view of this poor publication policy it has to be seriously
considered whether involved ethics committees should at-
tach greater importance to this topic and should refuse a
favorable opinion for protocols with such inadequate publi-
cation policies. This consideration also applies to other
shortcomings of the study protocols.
In general, these findings might also be relevant to the
competent authorities, but due to the legal situation the
BfArM is currently not in the position to grant approval
for NIS but is only notified of the fact that they are being
conducted. Thus, freedom of research and quality of research
may be in competition with each other to some extent . The
internal assessment at the BfArM mainly ensures that the
notified NIS are indeed non-interventional as opposed to
being clinical trials which would require approval. As long
as the study is truly non-interventional, the participating
patients are by definition not exposed to a greater risk.
Despite the generally less favorable outcome regarding
many score items, some results were more satisfying. For
example, over two-thirds of the NIS planned the involve-
ment of an ethics committee, and over 80 % provided data
on study duration, observational period for each patient,
number of visits of the patients, number of patients, number
of HCPs and reported the survey instruments. It also has
been recognized that over 90 % of the NIS provided data on
quality assurance, data management and statistical analysis.
Nevertheless, it would have been preferable if the informa-
tion provided on these topics had been more detailed.
With respect to the primary objective of these NIS, it
once again is obvious that the most frequently analyzed
objectives (>70 %) were effectiveness/efficacy as well as
safety and tolerability of the investigated medicinal prod-
ucts. This is in line with results published by Hasford and
Lamprecht in 1998 [6] and confirmed by Dietrich in 2009
[10]. The authors of both studies discussed that NIS are
usually not an appropriate scientific instrument for analyz-
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worth mentioning that the 1998 BfArM recommendations
on NIS listed “enhancing of findings regarding effective-
ness” as a possible objective for an NIS, but this was
omitted in the draft version in 2007 [16, 18].
Although NIS seem to be an appropriate instrument for
detecting new ADR and for calculating ADR incidences, the
role of controlled study designs has also been discussed
frequently in the past. Hasford and Lamprecht [6] as well
as Dietrich [10] stipulated that a control group should be
included to adjust ADR rates. Even though over 70 % of the
NIS investigated ADR as the primary or secondary objec-
tive, only 5 % of them included a control group. Other
“typical” NIS objectives such as “everyday life experience”
and “treatment compliance” were only reported in 41 and
13 %, respectively [6, 13, 18, 21].
It is remarkable that nearly one-third of the NIS analyzed
the treatment with antineoplastic and immunomodulating
agents which are generally expensive products. Similar re-
sults were published by Dietrich [10] and Müller 2009 [34]
and supported by Ruppert and colleagues in 2012 [35], who
stated that “oncology” was the medical field to be observed
most frequently in NIS. The high cost of the treatments has
to be borne by the respective insurance companies. It was
also remarkable that 10 % of the NIS focused on only two
biosimilar medicinal products, namely erythropoietin and
interferon. These findings support the often-mentioned sus-
picion that NIS are conducted for marketing reasons and in
order to generate a greater turnover.
More than one-half of the analyzed API were well-known
API (on the market for more than 10 years), but in contrast
more than one-half of the analyzed medicinal products were
“newly introduced” products, i.e. they had been on the
market for less than 5 years. In addition to this, 32 % of
the medicinal products were non-originator products.
A closer look at the relationship between the year of
marketing authorization of the medicinal product and the
respective API yields a few surprising facts. Thus, 17 % of
the NIS were conducted with new generic products up to
2.5 years after their market entry, but with API from 1998 or
even earlier. Furthermore, 9 % of the NIS were conducted
with originator medicinal products which had been on the
market for approximately 10 years (1997–1999), and 10 %
of the NIS were conducted with API which received their
marketing authorization as early as 1978, the first year after
Germany started requiring marketing authorizations [36].
Taking these findings together, it appears questionable
whether it was really intended to gain new scientific data
on API which have been on the market for longer than 10
years. This is all the more so as it is only allowed to conduct
NIS within the authorized medical indication [8], and the
simplified marketing authorization process for generic me-
dicinal products is based on the assumption of a well-known
safety and efficacy profile of such API. These doubts are
supported by the observation that over two-thirds of the NIS
that analyzed generic medicinal products focused on
effectiveness/efficacy as at least one study objective.
When analyzing the number of scheduled patients it be-
came obvious that nearly two-thirds of the 330,000 patients
were included in only 10 % of the NIS, with each of the latter
including more than 10,000 patients. A subgroup analysis
revealed that nearly one-third of the group of patients was
analyzed by only five NIS investigating X-ray contrast agents.
Four of the respective contrast API received their marketing
authorization between 1982 and 1995; only one API was on
the market for less than 5 years. Against this background we
cannot prove the suspicion false that a considerable number of
the NIS were conducted primarily for marketing reasons.
Although the medical indication and the dosage informa-
tion given for all NIS in the observational plan were com-
pliant with the respective SmPCs, overall 10 % of the NIS
were only partially or even non-consistent with current
medical practice. In these cases, either the performed docu-
mentation or the clinical investigations were beyond the
current usual medical practice, and the NIS were misused
as a substitute for clinical trials. It has to be considered that
on the one hand this is not in line with the legal require-
ments and on the other hand the respective healthcare insur-
ance has to cover the costs for the extended diagnostics.
Not of relevance for costs and scientific quality but from an
ethical point of view it remains remarkable that nearly 20% of
the NIS apply a pseudonymized data transfer from the inves-
tigator to the sponsor without written informed consent from
the participating patients. This privacy issue may interfere
with the patient–doctor relationship of trust and may further
damage the reputation of NIS in the public opinion.
Our results are in contrast to those results of two studies
published by Hahn and colleagues in 2008 and 2010 who
reported that the VFA recommendations on NIS were
implemented by the member companies [37, 38]. However,
the results of these two studies cannot be compared directly to
our results because the studies performed by Hahn and col-
leagues analyzed the recommendation adherence in planning
and conducting of NIS by self-assessment by the pharmaceu-
tical companies, while our study focused on the quality of
single NIS protocols independently of the pharmaceutical
companies.
Overall, the results of our study can be seen as a continu-
ation of the criticism on NIS. While Hasford and Lamprecht
identified poor conduct of NIS over the last two decades of the
past century [6, 39], Dietrich renewed the criticism in 2009
[10]. This ongoing criticism stimulated the authorities as well
as industry associations and others to publish detailed recom-
mendations [4, 13, 16–18, 20–26] for NIS. Nevertheless, the
results of our study have confirmed once again that despite
these updated recommendations, the quality of NIS protocols
remains in need of improvement.
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Limitations
In this study, we performed a cross-sectional analysis of
nearly all NIS study protocols submitted to the BfArM
within a period of 1 year to determine the current state of
NIS. However, our study does have some limitations..
During the data set selection and research phases, five NIS
which should have been analyzed according to the inclusion
criteria were not eligible for analysis due to in-house pro-
cesses at the BfArM. Another limiting factor is that only
NIS conducted and/or sponsored by pharmaceutical compa-
nies are subject to the obligation of submitting NIS pro-
tocols to the BfArM and could therefore be included in our
study. There is still a larger number of NIS initiated by non-
commercial sponsors which was not available for analysis.
Our results only show the findings based on variables for
which information was provided in the observational plans.
Thus, it might be possible that a certain NIS applied more
variables or provided other measures, such as publication
policies not mentioned in the observational plan. This is
especially relevant for the scoring system in terms of being
able to rate the compliance with BfArM/PEI and VFA/FSA
recommendations. An NIS could only be scored if data on a
score item was presented in the observational plan. It could
happen that some studies fulfilled the score items of the
recommendation (e.g. the definition of standard operating
procedures) but could not be scored due to the missing de-
scription thereof in the observational plan. Nevertheless, it is
considered good scientific standard as well as good clinical
practice to include all relevant information on planning,
conducting, reporting and archiving of a study in the respec-
tive protocol. Therefore, a lack of such a description in the
protocol is considered to be a quality issue. Furthermore, it
cannot be excluded that some protocols were changed after
notification to the BfArM, possibly based on suggestions by
the involved ethics committees.
With regard to the scoring system applied it should also
be mentioned that all score items were rated equally. The
discriminatory power of some score items was therefore
poor in some cases because they were fulfilled either by
nearly all or by hardly any of the NIS.
The assessment of the compliance of the diagnostic and
therapeutic procedures with clinical practice was performed
only in a semi-blinded design.
Conclusions and outlook
The results of this study once again demonstrate that the NIS
conducted during the 1-year study period were only of a
medium quality and that the recommendations which were
published to enhance the quality of NIS have been only par-
tially followed. On the positive side it has to be mentioned that
NIS conducted byVFAmember companies were of a relatively
better—but still not of the highest—quality. More or less most
of the NIS still analyze objectives less suitable for the study
design type, and our results do not eliminate the suspicion that
some of the NIS were conducted for marketing reasons.
It is disappointing that after all these years and publica-
tions and after criticism and published recommendations the
potential of the NIS to be an important scientific instrument
has still not been sufficiently exploited. As stated in the
Introduction, the NIS could be a scientific instrument for
complementing the results of RCTs. The NIS could contrib-
ute important data on the use of medicinal products in
everyday life, such as on medical prescription practices,
dosage adaptations or patients’ compliance and, with a
suitable study design, on safety aspects. Instead, researchers
and pharmaceutical companies are still trying to obtain data
on objectives that have been determined as unsuitable for
this type of study design in the past.
Based on the results of our analysis, we could not negate
the current suspicion that some NIS are conducted for mar-
keting reasons and not to gain scientific data; in fact, in some
cases, such as with generic medicinal products, we were able
to substantiate this suspicion. Against this background the
future of NIS has to be discussed in a critical manner. The
preservation of NIS as a scientific instrument is only reason-
able if the pharmaceutical companies finally start to integrate
all items of the recommendations in the planning of their NIS
and stop using the NIS as marketing or pseudoscientific in-
struments, especially if ten thousands of patients are involved
in the NIS. It may be helpful to consider increasing the
competency of the authorities and/or ethics committees, but
this would require further legal modifications.
Recently, the term “post-authorization safety studies”
(PASS) was incorporated into European law, and these
studies are now closer to NIS [40, 41]. It would be desirable,
and it can only be hoped that in the course of enhancing and
improving the quality of the PASS, the quality of the NIS
will also be improved and enhanced.
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